RYTM - Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04 revenue of $19.22M beats by $4.19M
2023-08-01 07:14:08 ET
- Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q2 GAAP EPS of -$0.82 misses by $0.04 .
- Revenue of $19.22M (+112.1% Y/Y) beats by $4.19M .
- Net product revenues relating to global sales of IMCIVREE were $19.2 million for the second quarter of 2023, as compared to $2.3 million for the second quarter of 2022. For the second quarter ended June 30, 2023, 86% of the Company’s product revenue was generated in the United States.
- Financial Guidance: For the year ending December 31, 2023, Rhythm continues to anticipate approximately $200 million to $220 million in Non-GAAP Operating Expenses, comprised of $120 million to $130 million from R&D expenses and $80 million to $90 million from S,G&A expenses. Based on its current operating plans.
- Rhythm expects that its existing cash, cash equivalents and short-term investments as of June 30, 2023, together with the anticipated $25 million milestone payment based on commercial sales from Healthcare Royalty Partners, will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.
For further details see:
Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04, revenue of $19.22M beats by $4.19M